This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Contracting margins, antitrust over GRAIL, and the Icahn invasion all crash estimates and shares
biotechnology cancer genetic-testing genomics oncology-screening smart-health
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Medical diagnostics leader in prostate cancer is driving 34% sales and 32% EPS growth
cancer medical oncology-screening smart-health
Biotech ETFs Pop on M&A Resurgence
by Neena Mishra
2023 could be a year of heightened biotech dealmaking activity
cancer cell-therapy etfs gene-editing
5 Diverse Medical Stocks to Buy for 2023 and Beyond
by Shaun Pruitt
The top and bottom-line growth make these Zacks Medical stocks very attractive.
biotechnology cancer cell-therapy dividend-investing dividends gene-therapy hmo hospitals immuno-therapy insurance large-cap medical pharmaceuticals vaccines
Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition
by Shaun Pruitt
Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.
cancer investing medical oncology-screening pharmaceuticals
Bull of the Day: Lantheus (LNTH)
by Kevin Cook
Stunning "beat-and-raise" quarter has analysts scrambling to raise estimates and price targets above $110
cancer medical oncology-screening
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
by Sundeep Ganoria
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
biotechnology biotechs cancer cell-therapy coronavirus immuno-therapy inflation medical
Buy this Medical Sector Pioneer Stock
by Shaun Pruitt
Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock.
cancer dividend-investing dividends immuno-therapy medical oncology-screening
How Markets Have Fared Under a Divided Congress
by Bryan Hayes
Markets typically applaud the 'certainty' that comes with a split Congress.
cancer dividend-investing dividends earnings immuno-therapy inflation investing large-cap medical oncology-screening pharmaceuticals